Novartis Ag (NVS) Receivables Refunds (2016 - 2025)
Historic Receivables Refunds for Novartis Ag (NVS) over the last 10 years, with Q4 2025 value amounting to $205.0 million.
- Novartis Ag's Receivables Refunds rose 5413.53% to $205.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $205.0 million, marking a year-over-year increase of 5413.53%. This contributed to the annual value of $205.0 million for FY2025, which is 5413.53% up from last year.
- As of Q4 2025, Novartis Ag's Receivables Refunds stood at $205.0 million, which was up 5413.53% from $140.0 million recorded in Q3 2025.
- In the past 5 years, Novartis Ag's Receivables Refunds registered a high of $426.0 million during Q4 2023, and its lowest value of $120.0 million during Q2 2025.
- Over the past 5 years, Novartis Ag's median Receivables Refunds value was $256.5 million (recorded in 2021), while the average stood at $248.0 million.
- In the last 5 years, Novartis Ag's Receivables Refunds skyrocketed by 5895.52% in 2023 and then tumbled by 6877.93% in 2024.
- Quarter analysis of 5 years shows Novartis Ag's Receivables Refunds stood at $278.0 million in 2021, then dropped by 3.6% to $268.0 million in 2022, then surged by 58.96% to $426.0 million in 2023, then tumbled by 68.78% to $133.0 million in 2024, then surged by 54.14% to $205.0 million in 2025.
- Its last three reported values are $205.0 million in Q4 2025, $140.0 million for Q3 2025, and $120.0 million during Q2 2025.